Opinion
Civil Action 20-4660-KSM
08-02-2022
HALMAN ALDUBI PROVIDENT AND PENSION FUNDS LTD., Plaintiff, v. TEVA PHARMACEUTICALS INDUSTRIES LIMITED, et al., Defendants.
ORDER
KAREN SPENCER MARSTON, J.
AND NOW, this 2nd day of August, 2022, upon consideration of Defendants' Motion to Stay Proceedings Other than Class Certification in Favor of the DOJ's Case (Doc. No. 83), Lead Plaintiff's Memorandum of Law in Opposition to Defendants' Motion to Stay Proceedings Other than Class Certification in Favor of the DOJ's Case (Doc. No. 84), and Defendants' Reply Memorandum in Further Support of Defendants' Motion to Stay Proceedings Other than Class Certification in Favor of the DOJ's Case (Doc. No. 85), it is hereby ORDERED as follows:
1. Defendants' Motion to Stay Proceedings Other than Class Certification in Favor of the DOJ's Case (Doc. No. 83) is GRANTED.
2. All proceedings other than discovery and briefing related to class certification are STAYED pending the resolution of United States v. Teva Pharmaceuticals USA, Inc., No. 1:20-cv-11548-NMG (D. Mass) (the “DOJ Action”).
3. Should the trial date in the DOJ Action be continued, the parties SHALL provide a joint status update informing the Court of the continuance within three days of the continuance.
The DOJ Action is currently scheduled to begin trial on September 18, 2023.
4. The parties SHALL provide a joint status update to the Court within seven days of the resolution of the DOJ Action.
5. The parties SHALL meet and confer and provide a proposed schedule for discovery and briefing regarding class certification no later than Monday, August 8, 2022.
IT IS SO ORDERED.